Erythroleukaemia complicating ANA-negative systemic lupus erythematosus [1]

Scandinavian Journal of Rheumatology

Volumn 36, Issue 6, 2007, Pages 478-480

  Eilertsen, G O ^a   Nossent, J C ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ARTHRALGIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; EPISCLERITIS; ERYTHROLEUKEMIA; GLOMERULONEPHRITIS; HUMAN; INFECTION; LETTER; LEUKOPENIA; LOW DRUG DOSE; MACROCYTIC ANEMIA; MIGRAINE; PHOTOSENSITIVITY; PRICK TEST; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN TEST; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; URTICARIA;

ANTIBODIES, ANTINUCLEAR; BONE MARROW; FEMALE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

EID: 37349118282     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701483063     Document Type: Letter

References (15)

1. Karakelides M, Monson KL, Volcheck GW, Weiler CR. Monoclonal gammopathies and malignancies in patients with chronic urticaria. Int J Dermatol 2006;45:1032-8.
2. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996;135:355-62.
3. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
4. Fries JF, Holman HR. Systemic lupus erythematosus: a clinical analysis. Major Probl Intern Med 1975;6:v-199.
5. Lee P, Urowitz MB, Bookman AA, Koehler BE, Smythe HA, Gordon DA, et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
6. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005;27:247-9.
7. Wisnieski JJ. Urticarial vasculitis. Curr Opin Rheumatol 2000;12:24-31.
8. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71.
9. Taguchi F, Miyoshi T, Nakajima N, Nishimura J, Nawata H. Acute promyelocytic leukemia developed in the course of systemic lupus erythematosus: a case report [in Japanese]. Rinsho Ketsueki 1990;31:1965-6.
10. Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005;19:1912-18.
11. Ng HS, Ng HW, Sinniah R, Feng PH. A case of systemic lupus erythematosus with sideroblastic anaemia terminating in erythroleukaemia. Ann Rheum Dis 1981;40:422-6.
12. Ando M, Narabayashi M, Watanabe T, Kamiya Y, Togitani K, Tanosaki R, et al. Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. Jpn J Clin Oncol 1999;29:28-32.
13. West WO. Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases. South Med J 1976;69:1331-2.
14. Takaoka T, Matsukawa Y, Tomita Y, Kitamura N, Yamazaki T, Takeuchi J, et al. Development of erythroleukaemia after myelodysplastic syndrome in a patient with Wegener's granulomatosis. Ann Rheum Dis 2001;60:899-900.
15. Devereux S. Therapy associated leukaemia. Blood Rev 1991;5:138-45.